Hostname: page-component-745bb68f8f-b95js Total loading time: 0 Render date: 2025-02-11T14:52:16.650Z Has data issue: false hasContentIssue false
  • English
  • Français

Levomepromazine in the Treatment of Neuroleptic Resistant Psychotics

Published online by Cambridge University Press:  08 February 2018

Peter Payne  and
David Verinder
Peter Payne
Affiliation:
Brandon Hospital for Mental Diseases, Brandon, Manitoba, Canada
David Verinder
Affiliation:
Brandon Hospital for Mental Diseases, Brandon, Manitoba, Canada
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Levomepromazine, levo-3-methoxy-10(2' methyl-3'-dimethylamino-l' propyl) phenothiazine is a phenothiazine derivative which was isolated in the Rhone-Poulenc Laboratories and studied pharmacologically by Sigwald et al. (2) in 1956.

Type
Original Articles
Information
Journal of Mental Science , Volume 106 , Issue 445 , October 1960 , pp. 1429 - 1431
Copyright
Copyright © Royal College of Psychiatrists, 1960 

References

1 Deschamps, A., and Madre, J., Psychiatric Therapy with a New Neuroleptic (R.P. 7044), La Presse Medicale, Vol. 65, 46; 1071.Google Scholar
2 Sigwald, J., et al., Activité d'une nouvelle phénothiazine en psychiatrie et en neurologie. Presse Médicale. 1 December, 1956.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.